ALPMF:OTC-Astellas Pharma Inc (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 10.945

Change

0.00 (0.00)%

Market Cap

USD 21.46B

Volume

145.00

Analyst Target

USD 50.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
RHHBY Roche Holding Ltd ADR

N/A

USD 258.74B
RHHVF Roche Holding AG Participation

-6.28 (-2.05%)

USD 258.74B
RHHBF Roche Holding AG

N/A

USD 258.74B
AZNCF AstraZeneca PLC

-0.14 (-0.09%)

USD 241.92B
SNYNF Sanofi

N/A

USD 142.76B
CHGCY Chugai Pharmaceutical Co Ltd A..

-0.12 (-0.51%)

USD 83.22B
DSNKY Daiichi Sankyo Co Ltd ADR

N/A

USD 63.77B
ALPMY Astellas Pharma Inc

N/A

USD 21.25B
RICFY Recordati Industria Chimica e ..

N/A

USD 11.87B
KYKOF Kyowa Kirin Co. Ltd

N/A

USD 11.02B

ETFs Containing ALPMF

1638:TSE 11.16 % 0.00 %

N/A

N/A
JPSR:LSE UBS MSCI Japan Socially R.. 0.00 % 0.00 %

+20.75 (+0%)

USD 68.13B
SUJA:LSE iShares MSCI Japan SRI UC.. 0.00 % 0.00 %

+5.38 (+0%)

N/A
SUJP:LSE iShares MSCI Japan SRI UC.. 0.00 % 0.00 %

+0.06 (+0%)

N/A
SRIJ:PA BNP Paribas Easy MSCI Jap.. 0.00 % 0.00 %

+0.26 (+0%)

USD 0.03B
UIMT:F UBS ETF SICAV - MSCI Paci.. 0.00 % 0.00 %

+0.59 (+0%)

USD 1.05B
SXR6:XETRA CS (IE) on MSCI Europe 0.00 % 0.00 %

+0.09 (+0%)

USD 1.03B
UIMT:XETRA UBS ETF SICAV - MSCI Paci.. 0.00 % 0.00 %

+0.94 (+0%)

USD 1.07B
1621:TSE NEXT FUNDS TOPIX-17 Pharm.. 0.00 % 0.00 %

+160.00 (+0%)

USD 2.53B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.72% 36% F 42% F
Dividend Return 4.16% 95% A 60% D-
Total Return -4.55% 38% F 44% F
Trailing 12 Months  
Capital Gain -19.17% 21% F 37% F
Dividend Return 3.69% 79% B- 50% F
Total Return -15.48% 26% F 39% F
Trailing 5 Years  
Capital Gain -22.54% 41% F 50% F
Dividend Return 191.55% 100% F 97% N/A
Total Return 169.01% 100% F 89% A-
Average Annual (5 Year Horizon)  
Capital Gain -8.42% N/A N/A 24% F
Dividend Return 32.58% N/A N/A 69% C-
Total Return 41.00% N/A N/A 95% A
Risk Return Profile  
Volatility (Standard Deviation) 67.15% N/A N/A 42% F
Risk Adjusted Return 48.51% N/A N/A 84% B
Market Capitalization 21.46B 65% D 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector